This company listing is no longer active
Redwood Pharma Management
Management criteria checks 1/4
Redwood Pharma's CEO is MV Vidaeus, appointed in Jan 2012, has a tenure of 12.58 years. directly owns 0.93% of the company’s shares, worth SEK29.18K. The average tenure of the management team and the board of directors is 10.6 years and 0.8 years respectively.
Key information
MV Vidaeus
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 12.6yrs |
| CEO ownership | 0.9% |
| Management average tenure | 10.6yrs |
| Board average tenure | less than a year |
Recent management updates
CEO
MV Vidaeus (58 yo)
12.6yrs
Tenure
Mr. Martin Vidaeus, also known as MV, MBA, is the Founder of Redwood Pharma AB. Mr. Vidaeus holdss many year's experience in life science business development in the US and Europe. He has successful histor...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & Chief Medical Officer | less than a year | no data | 0.062% SEK 1.9k | |
| Founder | 12.6yrs | no data | 0.93% SEK 29.2k | |
| Founder & COO | 12.6yrs | no data | 0.15% SEK 4.8k | |
| Chief Financial Officer | 8.3yrs | no data | no data |
10.6yrs
Average Tenure
65.5yo
Average Age
Experienced Management: REDW's management team is seasoned and experienced (10.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & Chief Medical Officer | less than a year | no data | 0.062% SEK 1.9k | |
| Founder | 12.6yrs | no data | 0.93% SEK 29.2k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
0.8yrs
Average Tenure
58yo
Average Age
Experienced Board: REDW's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/17 02:41 |
| End of Day Share Price | 2024/07/26 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Redwood Pharma AB is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Markus Augustsson | Carlsquare AB |